In conclusion, our study demonstrates that p300/CBP inhibitors exhibit specific efficacy in FLT3-ITD AML, maintaining efficacy even in cases resistant to FLT3 inhibitors with FLT3-ITD/TKD mutations or primary AML samples with high ITD allelic ratios. Here, EP300 is linked to acute myeloid leukemia.